MEDICAL ACCESS STRATEGY TO IMPROVE ACCESS TO INNOVATIVE AND EXPENSIVE THERAPY IN FRANCE

Author(s)

Cohen S1, Paubel P2, Monchecourt F3
1Faculty of pharmacy, Paris Descartes University, VINCENNES, France, 2Health Law Institute, INSERM UMR S 1145 / Faculty of Pharmacy, Paris Descartes University, Sorbonne Paris Cité, Paris, France, 3Teva Pharmaceuticals, Courbevoie, France

OBJECTIVES: Decision-making on the reimbursement level and price of innovative therapy by the French health reimbursement system is one of the longest in Europe[1]

Conference/Value in Health Info

2018-11, ISPOR Europe 2018, Barcelona, Spain

Value in Health, Vol. 21, S3 (October 2018)

Code

PCP68

Topic

Methodological & Statistical Research

Topic Subcategory

Confounding, Selection Bias Correction, Causal Inference

Disease

Multiple Diseases

Explore Related HEOR by Topic
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×